Join the 'Taltz' group to help and get support from people like you.
Posted 26 May 2017 by Drugs.com
FRIDAY, May 26, 2017 – A new drug might help ease the pain and disability of a form of arthritis often linked to psoriasis. According to Stanford University researchers, psoriatic arthritis is an inflammatory joint disorder tied to an out-of-control immune response. The disease affects about one in every 200 people and is often accompanied by the autoimmune skin disorder psoriasis. Psoriatic arthritis typically arises after the age of 30 and can bring stiffness, pain and swelling of the joints, leading to real disability if treatments don't help. The new study focused on more than 300 adult patients across 10 countries. These patients were no longer seeing an effect from standard biologic drugs or had never experienced a benefit in the first place. That's not uncommon. "Only about half of psoriatic arthritis patients who are given TNF inhibitors get better," study lead author Dr. Mark ... Read more
Posted 8 Jun 2016 by Drugs.com
WEDNESDAY, June 8, 2016 – A new drug that has shown "unprecedented" effects on the skin condition psoriasis seems to work well in the longer term, too, researchers report. The drug, called ixekizumab (Taltz), was approved in March by the U.S. Food and Drug Administration. That came after initial trials showed that over 12 weeks, the drug soundly beat standard medication for moderate-to-severe psoriasis. The new findings show the benefits are still there after 60 weeks. At that point, about 80 percent of patients were seeing at least a 75 percent improvement in their skin symptoms, the researchers said. So far, ixekizumab has shown "unprecedented efficacy" against more severe cases of psoriasis, said Dr. Joel Gelfand, a dermatologist who wasn't involved in the research. The drug, given by injection, targets an inflammatory protein called IL-17, said Gelfand, who directs the Psoriasis ... Read more
Posted 23 Mar 2016 by Drugs.com
March 22, 2016 – The U.S. Food and Drug Administration today approved Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches of skin redness and flaking. Psoriasis is an autoimmune disorder that occurs more commonly in patients with a family history of the disease, and most often begins in people between the ages of 15 and 35. The most common form of psoriasis is plaque psoriasis, in which patients develop thick, red skin with flaky, silver-white scales. “Today’s approval provides patients suffering from plaque psoriasis with another important treatment option to help relieve the skin irritation and discomfort from the condition,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. Taltz’s active ingredient is an antibody (ixekizumab) that bi ... Read more